Search

Consideration of comorbidity, disability, and frailty represents a significant part of the treatment of elderly multiple myeloma (MM) patients. The aim of study was to analyze the effect of the Charlson Comorbidity Index (CCI) and scale of Instrumental Activities of Daily Living (IADL) on the course of disease.The study included 110 newly diagnosed MM patients older than 65 years of age. According to the CCI most patients had at least 1 comorbidity (CCI score of 1) and most of them (51 of 110 patients; 46.4%) had an age-adjusted CCI (aaCCI) score of 5 to 6. Most of our patients were capable of performing routine daily activities (IADL ≥ 6). Patients were treated with thalidomide- and bortezomib- based combinations, or with conventional chemotherapy.International Staging System (ISS) score 3 correlated with high scores of CCI or aaCCI (R = 0.314, P.003; R = .317, P.002, respectively), and lower IADL (R = 0.259, P.007). The probability of adverse events was 70% greater for CCI score ≥ 2 (odds ratio [OR], 1.72); 28% for aaCCI ≥ 5 (OR, 1.28) and 22% higher for IADL3 (OR, 2.25). The patients with a CCI score of 0 to 1 had significantly longer overall survival (OS; log rank, 6.538; P.011). The patients with aaCCI ≥ 5 had significantly shorter OS (log rank, 4.209; P.040), and the patients with IADL3 had significantly longer OS (log rank, 6.62; P.001). In the proposed model, aaCCI ≥ 5 and IADL3 scores had a major effect on the OS (χ(2), 8.46; P = .037).CCI, aaCCI, and IADL scale are clinical parameters of prognostic significance. A proposed model for a personalized treatment approach is based on variables such as scores for aaCCI ≥ 5 and IADL3.

Aim: The aim of this study was to evaluate nutritional status at the presentation of lymphoma as predictor for therapy outcome. Methods: We have analised 115 pts, m- 59/ f- 56, with newly diagnosed lymphoproliferative disorders( Jan 2012-mar 2014.) with curable modality of therapy. Pts with paliative treatment were excluded. We have analised influence of their nutritional status on therapy outcome:complete remission (CR), partial remission (PR), very good partial remission (VGPR), early death (ED), early relaps (ER) and stable dissease (SD) or progressive dissease (PD). Alse we have calculated risk according age, clinical stage and agressivnes of primary dissease. According to ECOG PS we divided pts in two groups:ECOG PS less than 2, and 2 and more. Nutritional status was screenined using NRS2002 (nutritional assement proposed by ESPEN) and MNA (“mini nutritional assesment”). We also had information about infiltration of gastrointestinal tract (GIT). Results: We had 95 pts with agressive lymphoma and 20 pts with indolent lymphoma. Median age was 60,5 (23-85)years, ECOG PS 0-1 47pts vs. 68 pts with ECOG PS 2 and more. We has 38pts in CS less than III and 77 pts with CS III and more. Median weight loss was 8,3(0-33)%, median BMI was 24,3 (16,7-38,6)kg/m2. Median percentage of weight loss per month was 2,7 (0-10)% . We have divided pts in two groups with loss until 3% per month or over 3% per month. As outcome of therapy 91pts achieved CR, VGPR or PR as favorable outcome and 24 pts had ED, ER, SD or PD. According NRS2002 we had two groups less than 3 vs. 4 and more. For MNA 11 and more vs. less than11. Binary logistic model for outcome previously explaned was significant (Wald 33,7, p Conclusions: Besides ECOG PS nutritional assesment can be predictor for therapy outcome in lymphoma pts. MNA screening was better predictor than NRS2002. Implementation of nutritional assesment in initial staging for pts with limforpoliferative dissease can reveal patients that need nutritional suport along with treatment. Study has limitation for implementing comorbidity indexes in model and larger group can be more conclusive. Disclosure: All authors have declared no conflicts of interest.